Core B: Biosafety Level 4 Core

BSL-4核心（核心B）：项目总结/摘要 埃博拉病毒（EBOV）疾病的发病机制以免疫反应失调为特征 这包括抑制先天免疫系统导致“免疫瘫痪”， 矛盾的是，炎症途径的激活是“细胞因子风暴”的特征。这个目标 计划项目是研究免疫反应失调的分子机制， EBOV感染。EBOV感染必须在生物安全等级4/动物生物安全等级下进行 4（BSL-4/ABSL-4）符合政府和机构生物安全、生物安保 和选择代理法规;因此，本计划项目需要BSL-4核心（核心B）。核心B 将使用加尔维斯顿国家实验室（GNL）的BSL-4和ABSL-4设施，该实验室是 德克萨斯大学医学分支（UTMB）。核心B与研究的互动 项目（RP）将由行政核心（核心A）协调。 基本的努力包括在该计划项目将执行感染的主要 免疫细胞和非免疫细胞来自具有EBOV的去识别人类受试者和具有EBOV的突变体， 干扰素抑制域被禁用。接下来，将从恒河猴身上提取细胞和组织 感染相同的病毒，这将用于补充体外数据。被感染的细胞会 用于研究转录（研究项目[RP]1），转录后（RP 2），和 翻译后机制（RP 3）导致对EBOV的免疫应答失调。的 涉及感染性材料的实验程序的初始步骤，用于所有RP和靶向 将在体外进行导致基因表达水平反应失调的关键节点的研究 在GNL BSL-4设施中。靶向的体内验证将在小鼠和恒河猴中进行 猕猴将在GNL ABSL-4设施中进行。 将在核心B中执行的程序对于实现 拟议的研究，包括：（a）详细了解导致 对EBOV的免疫应答失调，（B）阐明转录后机制的作用 在对EBOV的免疫应答失调中，（c）阐明了翻译后表达的作用， EBOV免疫应答失调的机制，以及（d）构建和实验 验证EBOV感染和其他严重病毒感染发病机制的综合模型 感染，如马尔堡、拉沙热、登革热和COVID-19。完成核心B特定目标 将为RP 1，RP 2和RP 3提供关键支持，以确定转录， 在对EBOV的免疫应答失调中的转录后和翻译后机制。

BSL-4 CORE (Core B): PROJECT SUMMARY/ABSTRACT The pathogenesis of Ebola virus (EBOV) disease is characterized by a dysregulated immune response that includes the suppression of the innate immune system leading to “immune paralysis” and paradoxically activation of inflammatory pathways characteristic of a “cytokine storm”. The goal of this Program Project is to investigate the molecular mechanisms of the dysregulated immune response to EBOV infections. EBOV infections must be performed under Biosafety Level 4/Animal Biosafety level 4 (BSL-4/ABSL-4) containment in accordance with government and institutional biosafety, biosecurity and select agent regulations; therefore, this Program Project requires a BSL-4 Core (Core B). Core B will use the BSL-4 and ABSL-4 facilities of the Galveston National Laboratory (GNL), which is part of the University of Texas Medical Branch (UTMB). Interactions between Core B and the Research Projects (RPs) will be coordinated by the Administrative Core (Core A). Fundamental to the efforts included in the Program Project will be performing infections of primary immune and nonimmune cells from deidentified human subjects with EBOV and a mutant with a disabled interferon-inhibiting domain. Next, cells and tissues will be taken from rhesus macaques infected with the same viruses, which will be used to complement in vitro data. The infected cells will be used for investigation of transcriptional (Research Project [RP]1), posttranscriptional (RP2), and posttranslational mechanisms (RP3) that lead to the dysregulated immune response to EBOV. The initial steps of the experimental procedures, which involve infectious materials, for all RPs and targeting of critical nodes leading to dysregulated responses at gene expression levels in vitro will be performed in GNL BSL-4 facilities. The in vivo validation of the targeting will be performed in mice and rhesus macaques will be performed in GNL ABSL-4 facilities. The procedures that will be performed in Core B are critical for achieving the major goals of the proposed studies, including: (a) detailed knowledge of transcriptional mechanisms leading to the dysregulated immune response to EBOV, (b) elucidation of the role of posttranscriptional mechanisms in the dysregulated immune response to EBOV, (c) elucidation of the role of posttranslational mechanisms in the dysregulated immune response to EBOV, and (d) building and experimental validation of a comprehensive model for the pathogenesis of EBOV infection and other severe viral infections, such as Marburg, Lassa fever, dengue, and COVID-19. Completion of Core B Specific Aims will provide critical support for RP1, RP2, and RP3 to identify the role of transcriptional, posttranscriptional, and posttranslational mechanisms in the dysregulated immune response to EBOV.